PDS Biotechnology Co. (NASDAQ:PDSB) Sees Significant Increase in Short Interest

PDS Biotechnology Co. (NASDAQ:PDSB) was the recipient of a significant growth in short interest in February. As of February 28th, there was short interest totalling 4,670,000 shares, a growth of 20.7% from the February 13th total of 3,870,000 shares. Based on an average daily volume of 630,100 shares, the short-interest ratio is currently 7.4 days. Currently, 13.8% of the company’s shares are sold short.

PDS Biotechnology Stock Down 2.9 %

PDS Biotechnology stock opened at $1.35 on Thursday. The company has a market cap of $51.56 million, a P/E ratio of -1.16 and a beta of 1.68. PDS Biotechnology has a 1-year low of $1.13 and a 1-year high of $5.00. The company has a fifty day simple moving average of $1.42 and a 200 day simple moving average of $2.24. The company has a current ratio of 2.84, a quick ratio of 2.84 and a debt-to-equity ratio of 0.55.

Institutional Trading of PDS Biotechnology

A number of large investors have recently added to or reduced their stakes in PDSB. Raymond James Financial Inc. acquired a new stake in PDS Biotechnology in the fourth quarter valued at $26,000. Jane Street Group LLC acquired a new stake in shares of PDS Biotechnology during the 4th quarter worth about $58,000. Marshall Wace LLP lifted its stake in shares of PDS Biotechnology by 38.4% during the 4th quarter. Marshall Wace LLP now owns 39,024 shares of the company’s stock worth $64,000 after buying an additional 10,837 shares during the last quarter. Virtu Financial LLC acquired a new stake in shares of PDS Biotechnology during the 4th quarter worth about $89,000. Finally, Two Sigma Investments LP lifted its stake in shares of PDS Biotechnology by 273.5% during the 4th quarter. Two Sigma Investments LP now owns 65,732 shares of the company’s stock worth $107,000 after buying an additional 48,132 shares during the last quarter. Institutional investors and hedge funds own 26.84% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have commented on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $21.00 target price on shares of PDS Biotechnology in a research note on Thursday, March 13th. B. Riley lowered their target price on shares of PDS Biotechnology from $9.00 to $7.00 and set a “buy” rating for the company in a research note on Monday, November 25th. One analyst has rated the stock with a sell rating, three have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $11.67.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.